The SAFE-CLTI (Critical Limb-Threatening Ischemia) initiative, a collaboration between the Smith Center and FDA, investigates:
- Trends in site-of-service for CLTI care
- Disparities in access and outcomes
- Comparative effectiveness of endovascular strategies
- Patient-centered outcomes like mobility and quality of life
Explore the SAFE-CLTI papers:
📄 Clinical Setting & Outcomes in Endovascular Care (Circ Outcomes, 2023): https://doi.org/10.1161/CIRCOUTCOMES.122.009199
📄 Dynamic Trends in Femoropopliteal Revascularization (JACC, 2025): https://doi.org/10.1016/j.jacc.2024.10.102
📄  Changing Clinical Indications for Femoropopliteal Revascularization (JACC: Cardiovas. Interv, 2025): https://doi.org/10.1016/j.jcin.2025.04.019
📄 Association Between Socioeconomic Vulnerability and Major Clinical Outcomes following Endovascular Treatment for CLTI (EJVS, 2025): https://doi.org/10.1016/j.ejvs.2025.09.059
📄 Impact of socioeconomic wealth on chronic limb-threatening ischemia revascularization outcomes (JVS, 2025): https://doi.org/10.1016/j.jvs.2025.08.029
📄 NEW! The Shifting Landscape of Chronic Limb-Threatening Ischemia Revascularization Toward Ambulatory Surgical Centers and Outpatient-Based Laboratories (JACC: Card Int, 2025) https://doi.org/10.1016/j.jcin.2025.09.010
📄 Persistent Racial Disparities in CLTI Outcomes and Utilization (To be published in AJC, 2026): https://doi.org/10.1016/j.amjcard.2025.09.047
Together, these studies inform clinical practice, policy, and equitable access for patients with CLTI.